StockData
Niagen Bioscience, Inc. logo

Niagen Bioscience, Inc. (NAGE) stock

NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3013% below fair value
$2.01−0.06 (-2.66%)

Close on Nov 16, 2026Market cap $159.04MP/E 16.8Yield –

Niagen Bioscience enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Niagen Bioscience's enterprise value was $98.57M on Nov 11, 2026, against $474.87M a year earlier. Over the last 5 years it ranged from $66.76M to $1.07B, with a median of $179.86M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$98.57M-77.7%
2025Dec 31, 2025$442.21M+19.2%
2024Dec 31, 2024$370.93M+361.6%
2023Dec 29, 2023$80.35M-20.7%
2022Dec 30, 2022$101.26M-54.3%
2021Dec 31, 2021$221.57M–
2020Dec 31, 2020-$15.18M–
2019Dec 31, 2019-$18.62M–
2018Dec 31, 2018-$28.03M-110.9%
2017Dec 29, 2017$256.18M+110.0%
2016Dec 30, 2016$122.00M-5.1%
2015Dec 31, 2015$128.60M+41.5%
2014Dec 31, 2014$90.87M-34.9%
2013Dec 31, 2013$139.68M+195.1%
2012Dec 31, 2012$47.34M+24.4%
2011Dec 30, 2011$38.05M–

More Niagen Bioscience figures

See a number that looks wrong?